

MIR001-ADME/TOX TECHNOLOGIES
A MARKET INSIGHT REPORT– JULY 2010
CONTENTS

I. SCOPE AND METHODOLOGY

II. REPORT SYNOPSIS

1. ADME/Tox Technologies

Absorption

Distribution

Metabolism

ExcretionToxicity

2. Significant Methods for ADME/Tox

Predictive Technologies

Other Related ADME/Tox Methods

3. ADME/Tox Technologies – Global Market Analysis

Exhibit 1: ADME/Tox Technologies (2005-2012) – Global Market Analysis
(Current & Future) in US\$ Billion (*Graphical Representation included*)

Analysis by Technology

In Vivo ADME/Tox – An Ever Growing

Global Market Analysis.

Exhibit 2: In Vivo ADME/Tox (2005-2012) – Global Market Analysis (Current & Future)
by Geographic Region for United States, Europe, Asia-Pacific, Canada and Rest of World
in US\$ Million (*Graphical Representation included*)

Exhibit 3: In Vivo ADME/Tox (2006, 2009 and 2012): Percentage Breakdown of
Global Market Value by Geographic Region for United States, Europe, Asia-Pacific,
Canada and Rest of World (*Graphical Representation included*)

Exhibit 4: List of Major Global In Vivo Companies

In Vitro ADME/Tox – An Emerging Technology

Global Market Analysis

Exhibit 5: In Vitro ADME/Tox (2005-2012) – Global Market Analysis (Current & Future)
by Geographic Region for United States, Europe, Asia-Pacific, Canada and Rest of World
in US\$ Million (*Graphical Representation included*)

Exhibit 6: In Vitro ADME/Tox (2006, 2009 and 2012): Percentage Breakdown of
Global Market Value by Geographic Region for United States, Europe, Asia-Pacific,
Canada and Rest of World (*Graphical Representation included*)

Exhibit 7: List of Major Global In Vitro Companies

In Silico ADME/Tox – The Fastest Growing Technology

Global Market Analysis

Exhibit 8: In Silico ADME/Tox (2005-2012) – Global Market Analysis (Current & Future)
by Geographic Region for United States, Europe, Asia-Pacific, Canada and Rest of World
in US\$ Million (*Graphical Representation included*)

Exhibit 9: In Silico ADME/Tox (2006, 2009 and 2012): Percentage Breakdown of
Global Market Value by Geographic Region for United States, Europe, Asia-Pacific,
Canada and Rest of World (*Graphical Representation included*)

Exhibit 10: List of Major Global In Vitro Companies

4. Regional Market Analysis

North America

Exhibit 11: ADME/Tox Technologies (2005-2012) – North American Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

Analysis by Technology

In Vivo

Exhibit 12: In Vivo ADME/Tox (2005-2012) – North American Market Analysis (Current & Future) for United States and Canada in US\$ Million (*Graphical Representation included*)

Exhibit 13: In Vivo ADME/Tox (2006, 2009 and 2012): Percentage Breakdown of North American Market Value for United States and Canada

In Vitro

Exhibit 14: In Vitro ADME/Tox (2005-2012) – North American Market Analysis (Current & Future) for United States and Canada in US\$ Million (*Graphical Representation included*)

Exhibit 15: In Vitro ADME/Tox (2006, 2009 and 2012): Percentage Breakdown of North American Market Value for United States and Canada

In Silico

Exhibit 16: In Silico ADME/Tox (2005-2012) – North American Market Analysis (Current & Future) for United States and Canada in US\$ Million (*Graphical Representation included*)

Exhibit 17: In Silico ADME/Tox (2006, 2009 and 2012): Percentage Breakdown of North American Market Value for United States and Canada

Europe

Exhibit 18: ADME/Tox Technologies (2005-2012) – European Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)
Analysis by Technology

In Vivo

Exhibit 19: In Vivo ADME/Tox Technologies (2005-2012) – European Market Analysis (Current & Future) by Geographic Region for UK, Germany, France, Sweden, Finland, Italy and Rest of Europe in US\$ Million (*Graphical Representation included*)

Exhibit 20: In Vivo ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of European Market Value by Geographic Region for UK, Germany, France, Sweden, Finland, Italy and Rest of Europe (*Graphical Representation included*)

In Vitro

Exhibit 21: In Vitro ADME/Tox Technologies (2005-2012) – European Market Analysis (Current & Future) by Geographic Region for UK, Germany, France, Sweden, Finland, Italy and Rest of Europe in US\$ Million (*Graphical Representation included*)

Exhibit 22: In Vitro ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of European Market Value by Geographic Region for UK, Germany, France, Sweden, Finland, Italy and Rest of Europe (*Graphical Representation included*)

In Silico

Exhibit 23: In Silico ADME/Tox Technologies (2005-2012) – European Market Analysis (Current & Future) by Geographic Region for UK, Germany, France, Sweden, Finland, Italy and Rest of Europe in US\$ Million (*Graphical Representation included*)

Exhibit 24: In Silico ADME/Tox Technologies (2006, 2009 and 2012): Percentage

Breakdown of European Market Value by Geographic Region for UK, Germany, France, Sweden, Finland, Italy and Rest of Europe (*Graphical Representation included*)

Asia-Pacific

Exhibit 25: ADME/Tox Technologies (2005-2012) – Asia-Pacific Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)
Analysis by Technology

In Vivo

Exhibit 26: In Vivo ADME/Tox (2005-2012) – Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Japan, China, India, Australia, and Rest of Asia-Pacific in US\$ Million (*Graphical Representation included*)
Exhibit 27: In Vivo ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Japan, China, India, Australia and Rest of Asia-Pacific (*Graphical Representation included*)

In Vitro

Exhibit 28: In Vitro ADME/Tox (2005-2012) – Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Japan, China, India, Australia, and Rest of Asia-Pacific in US\$ Million (*Graphical Representation included*)
Exhibit 29: In Vitro ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Japan, China, India, Australia and Rest of Asia-Pacific (*Graphical Representation included*)

In Silico

Exhibit 30: In Silico ADME/Tox (2005-2012) – Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Japan, China, India, Australia, and Rest of Asia-Pacific in US\$ Million (*Graphical Representation included*)
Exhibit 31: In Silico ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Japan, China, India, Australia and Rest of Asia-Pacific (*Graphical Representation included*)

Rest of World

Exhibit 32: ADME/Tox Technologies (2005-2012) – Rest of World Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

III. PRODUCT/TECHNOLOGY RESEARCH

1. ADME/Tox – The Basics

Absorption
Distribution
Metabolism
Excretion
Toxicity

Global ADME/TOX Market

Exhibit 33: Global Market for ADME/Tox Technologies: Geographic Regions (Europe, Canada, United States, Asia-Pacific, and Rest of World) Ranked by Projected CAGR for 2005 through 2012 (*Graphical Representation included*)
Factors Determined by ADME/TOX
ADME/TOX Properties - Determined by
The Increasing Need to Predict ADME/TOX Profiles
Biological Assay Systems for the Evaluation of Cytochrome P450 Enzyme Isoforms
Technologies for Lead Generation

Common Technologies for Lead Generation Include
Technologies for Preclinical Development of Drug Candidates
Preclinical ADME/TOX Evaluation Tools
Preclinical ADME/TOX Tools are Generally Validated for

2. ADME/Tox Methods

High Throughput Screening

Global HTS Market

Exhibit 34: Global Market for HTS: Geographic Regions (Asia-Pacific, Europe, Canada, United States, and Rest of World) Ranked by Projected CAGR for 2005 through 2012 (*Graphical Representation included*)

Screening Technologies

The Various Types of Screening Technologies

Primary Screening

Secondary Screening

Biochemical Assays

Cell based Assays

High Content Scre

Predictive Technologies

Exhibit 35: Global Market for ADME/Tox Technologies: Predictive Technologies (In Silico, In Vitro and In Vivo) Ranked by Projected CAGR for 2005 through 2012 (*Graphical Representation included*)

In Vivo ADMET

Global In Vivo ADMET Market

Exhibit 36: Global Market for In Vivo ADME/TOX Technologies: Geographic Regions, (Canada, Europe, US, Asia-Pacific and Rest of World Ranked by Projected CAGR for 2005 through 2012 (*Graphical Representation included*))

Importance of In Vivo Tests

Exhibit 37: In Vivo ADME/Tox Methods

Modern In Vivo ADME/Tox Models

Zebrafish

Rodent Mo

Drosophila

C.elegans

Conventional In Vivo ADME/TOX Models

Radiolabels

Cassette

Semi Simultaneous Dosing

Why do we Need Animals for Trials?

In Vitro ADMET

Global In Vitro ADMET Market.

Exhibit 38: Global Market for In Vitro ADME/Tox Technologies: Geographic Regions (Canada, Europe, Asia-Pacific, US and Rest of World Ranked by Projected CAGR for 2005 through 2012 (*Graphical Representation included*))

In Vitro Assays

Veterinary In Vitro Testing

Exhibit 39: Veterinary In Vitro Testing Technologies (2005-2012) – Global Value Analysis in US\$ Million.

In Vitro Applications for Drug Discovery and Development

Human and Animal Metabolism

Permeation Studies

Other ADME Services

Exhibit 40: In Vitro ADME/TOX Methods

Examples of Human In Vitro ADME/TOX Assays Include

In Silico ADMET

Global In Silico ADMET Market

Exhibit 41: Global In Silico ADME/TOX Market: Geographic Regions (Europe,US, Asia- Pacific, Canada, and Rest of World Ranked by CAGR for 2005 through 2012 (*Graphical Representation included*))

In Silico Applications along Preclinical Stages

Target Identification

Lead Optimization

Target Validation

ADME/TOX Analysis

In Silico Predictive Models

Broad Segmentation of In Silico technology

The Market For In Silico by Segment.

Exhibit 42: In Silico ADME/Tox (2005-2012) – Global Market Analysis by Segment for Organ and Tissue Cells, Cellular Networks, and Whole Cells in US\$ Million (*Graphical Representation included*)

Exhibit 43: In Silico ADME/TOX (2006, 2009 and 2012): Percentage Breakdown of Global Market Value by Segment for Organ and Tissue Cells, Cellular Networks, and Whole Cells (*Graphical Representation included*)

Applications of In Silico Models in Drug Discovery Process

Potential Applications of In Silico Technology

Prediction of In Silico Profiles by Metabolic behavior

The Market for In Silico Technologies

The Prospects

The Constraints

3. Toxicity

Preclinical Toxicology

Predictive Toxicology

Determining Factors for Effective Predictive Toxicology in Preclinical Stage

Remedial Measures

Exhibit 44: Common Types of Toxicity Targeted for ADME/TOX Predictive Techniques

Computational Toxicology

QSAR

In Vitro Toxicology

In Vitro Toxicology – Liver Cell Models

Tissue Culture Systems Used in In Vitro Toxicology

In Vitro Toxicology Applications

Genomics in Toxicity Test

Examining Neurotoxicity

Exhibit 45: Common Approved In Vitro and In Vivo Procedures

Alternatives for Animals in Toxicity Testing

Exhibit 46: The Common Animals Used for ADME and Toxicity Testing (*Graphical Representation included*)

Exhibit 47: Non-animal Methods being Considered for Validation

4. ADME/TOX – An Essence of Pharmaceutical Industry

The Reasons for the Decline in Success Rates

The Process of Drug Discovery

Target Identification

Target Validation

Lead Identification

Lead Optimization

Clinical Trials

Phase I

Phase II

Phase III

Exhibit 48: The Critical Path for a Drug to Enter Clinical Trials

Exhibit 49: Global Expenditure on Development and Approval of New Drugs: 2005 – 2012 (In US\$ Million) *(Graphical Representation included)*

Exhibit 50: Estimated Time Required for Development of Drugs by Primary Indication (In Years) *(Graphical Representation included)*

Exhibit 51: Global R & D Expenditure of Every New Chemical Entity (NEC) Launched: 2005 to 2012 (In US\$ Million) *(Graphical Representation included)*

Exhibit 52: Drug Developmental Costs by Phase (Pre-approval) *(Graphical Representation included)*

5. ADME/TOX in Drug Discovery Process

Stages in Preclinical Studies

The Factors Influencing Drug Approval Rates

Exhibit 53: New Drug Attrition Rate: Percentage Breakdown of Factors Contributing to New Drug Failure for Inaptancy of Bioavailability, Toxicity, Commercial Drawbacks and Other *(Graphical Representation included)*

Exhibit 54: Attrition of Compounds from Discovery to Launch Phase of a Drug (In number of compounds) *(Graphical Representation included)*

Overlapping of Predictive ADME/TOX Technologies

Applications by Technology

Exhibit 55: Overlapping of Predictive ADME/TOX Technology Applications Across Various Stages of Drug Discovery *(Graphical Representation included)*

6. ADME/TOX and Drug Discovery Technologies

Pharmacogenomics

Pharmacokinetics

A – Category

D – Category

M – Category

E – Category

Exhibit 56: Classification of Protein Targets by Category

Proteomics

Bioinformatics

7. Challenges Facing the ADME/TOX Industry

IV. MARKET DYNAMICS

1. Global Market Analysis

Exhibit 57: ADME/Tox Technologies (2005-2012) – Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific, Canada and Rest of World in US\$ Million *(Graphical Representation included)*

Exhibit 58: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific, Canada and Rest of World *(Graphical Representation included)*

Global Markets in Related Technologies

Laboratory Information Management Systems

Global Market for LIM66

Exhibit 59: Laboratory Information Management System (LIMS) (2005-2012) –

Global Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

High Throughput Screening

Global HTS Market

Exhibit 60: High Throughput Screening (HTS) (2005-2012) – Global Market Analysis (Current & Future) in US\$ Billion (*Graphical Representation included*)

HTS Analysis by Geographic Region

Exhibit 61: High Throughput Screening (HTS) (2005-2012) – Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific, Canada and Rest of World in US\$ Million (*Graphical Representation included*)

Exhibit 62: High Throughput Screening (HTS) (2006, 2009 and 2012): Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific, Canada and Rest of World (*Graphical Representation included*)

Global Market for HTS Products

Exhibit 63: HTS Products (2005-2012) – Global Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

Global Market for Re-Screening of Hits

Exhibit 64: Re-Screening of Hits (2005-2012) – Global Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

Global Market for HTS Services and Consumables

Exhibit 65: HTS Services and Consumables (2005-2012) – Global Market Analysis (Current & Future) in US\$ Billion (*Graphical Representation included*)

Global Market for HTS Services and Call Based Consumables

Exhibit 66: HTS Services and Cell Based Consumables (2005-2012) – Global Market Analysis (Current & Future) in US\$ Billion (*Graphical Representation included*)

Global Spending on HTS for Lead Discovery

Exhibit 67: High Throughput Screening (HTS) (2005-2012) – Analysis of Global Spending for Lead Discovery by Geographic Region for United States, Europe, and Rest of World in US\$ Billion (*Graphical Representation included*)

Exhibit 68: High Throughput Screening (HTS) (2006, 2009 and 2012): Percentage Breakdown of Global Value of Spending for Lead Discovery by Geographic Region for United States, Europe, Asia-Pacific, Canada and Rest of World (*Graphical Representation included*)

Cell Based Assays

Global Market for Cell Based Assays

Exhibit 69: Cell-Based Assays (2005-2012) – Global Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

Cell Based Assay Analysis by Geographic Region

Exhibit 70: Cell-Based Assays (2005-2012) – Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific, Canada and Rest of World in US\$ Million (*Graphical Representation included*)

Exhibit 71: Cell-Based Assays (2006, 2009 and 2012): Percentage Breakdown of Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific, Canada and Rest of World (*Graphical Representation included*)

Global Pharmaceutical Cell Based Screening Market

Exhibit 72: Pharmaceutical Cell-Based Screening (2005-2012) – Global Market Analysis (Current & Future) in US\$ Billion (*Graphical Representation included*)

Global Drug Discovery Market

Global Drug Discovery Expenditure

Exhibit 73: Drug Discovery (2005-2012) – Global Expenditure in US\$ Billion (*Graphical Representation included*)

Global Biotech Industry at a Glance

Major Research Areas in Biotechnology

Exhibit 74: Global Biotechnology Industry (2005): Percentage Breakdown of Major Research Areas (*Graphical Representation included*)

2. The Need of the Hour

3. ADME/Tox – The Emerging Trends

Other Side of the Coin

4. Major Companies in ADME/Tox Industry

Accelrys, Inc. (USA)

ADMET Technologies (USA)

Advanced Chemistry Development, Inc. (ACD/Labs) (Canada)

Agilent Technologies, Inc. (USA)

AMRI Hungary, Inc. (Hungary)

Applied Biosystems Group (USA)

Argenta Discovery Ltd. (UK)

Aureus Pharma (France)

Bayer Technology Services GmbH (Germany)

BD Biosciences (USA)

Biacore International AB (Sweden)

BioFocus DPI (UK)

Bio-Rad Laboratories, Inc. (USA)

Bridge Pharmaceuticals (USA)

Caliper Life Sciences, Inc. (USA)

Cellomics, Inc. (USA)

Celsis International plc (UK)

Cerep SA (France)

Charles River Laboratories, Inc. (USA)

ChemSilico LLC (The) (USA)

Chenomx, Inc. (Canada)

CompuDrug International, Inc. (USA)

Cyprotex plc (UK)

Gene Logic, Inc. (USA)

Iconix Pharmaceuticals, Inc. (USA)

ID Business Solutions Ltd. (UK)

Invitrogen, Inc. (USA)

Kendle International, Inc. (USA)

Kibron, Inc. (Finland)

LHASA Ltd. (UK)

MDL Information Systems (USA)

Millipore Corporation (USA)
Molecular Discovery Ltd. (UK)
MultiCASE, Inc. (USA)
Noray Bioinformatics S.L. (Spain)
Perkin Elmer, Inc. (USA)
Pharma Algorithms (Canada)
Promega Corporation (USA)
Qualyst, Inc. (USA)
Ranbaxy Laboratories Ltd. (India)
Schrodinger LLC (USA)
Simulations Plus, Inc. (USA)
Sirius Analytical Instruments Ltd. (UK)
Stem Cell Innovations, Inc. (USA)
Strand Life Sciences (India)
Sygnis Pharm AG (Germany)
Tecan AG (Switzerland)
Thermo Fisher Scientific, Inc. (USA)
Tripos, Inc. (USA)
Waters Corporation (USA)
Xceleron Ltd. (UK)
More.....

5. Major Activities in ADME/Tox Industry

6. Major Product Introductions/Developments in ADME/Tox Industry

Pharma Algorithms Releases New ADME Boxes Version 4.0
Simulations Plus Releases New Important Upgrade of ClassPharmer™ Software
Applied Biosystems and Sciex Jointly Launch the New Cliiquid™ Drug Screen and Quant Software for Application in Routine Forensic Toxicology
BioReliance Introduces Novel Genotoxicity Screening Service
Caliper Life Sciences Introduces CDAS for Offering Complete Drug Discovery and Development Services
Simulations Plus Introduces New DNA Mutation Predictor
Simulations Plus Launches ADMET Predictor™ Version 2.3
Pharma Algorithms Announces ToxBio Version 2.0
Aureus Pharma Introduces New Tool to Identify Risks of Drug-Drug Interactions
DTE™ - New technology for Gene Expression Profiling for Drugs
Strand Introduces New Platform for In Silico Lead Optimization
NMS Introduces the New Brand Accelera
Simulations Plus Introduces New Predictive Models Expected to Improve Anti-HIV Activity Discovery Capab
InterMune Employs B-CLEAR® Technology for Drug Discovery Applications
Quantum Pharmaceuticals Releases an Innovative Platform
Agilent Launches Oligo array based Chip-on-chip Microarrays
Invitrogen Launches Advanced Transfection Reagents
Thermo Electron (Thermo Fisher Scientific) Introduces Updates to Darwin LIMS™
Accelrys Introduces Discovery Studio® 1.6
Bio-Rad releases version 7.5 of its KnowItAll Informatics System
Applied Biosystems and GeneGo Enter into Collaboration for Tissue Gene Expression
Aureus Pharma Unveils AurSCOPE® KinaseBionas Launches In Vitro Profiling Device
Caliper Unveils Xenogen
Genetix Produces CloneFill
Genetix Introduces Cell Dispense
Millipore Introduces 96-Well Millicell Plate

Peakdale Launches Peakfinder® Kinase Arrays
Applied Biosystems Adds a Million Genotyping Assays to Its TaqMan® Collection
Invitrogen Signs Agreement to Add ClonepixFL Technology of Genetix to Process Development Services
Aureus Pharma Issues License on AurSCOPE
Aureus Pharma Issues License on hERG and AurSCOPE ADME
Simulations Plus Launches Latest Versions of ADMET Software
Schrödinger Updates Schrödinger Suite 2006
Thermo Electron (Thermo Fisher Scientific) Launches Galileo LIMS v 3.2
Bio-Rad Incorporates MoLSAR™ Technology into KnowItAll
Malvern Instruments' Zetasizer Nano S Selected For Drug Delivery Research Use
Inpharmatica Expands Admensa Interactive™ Drug Discovery Tools
Peakdale Announces Completion of Peakexplorer™ GPCR Collection
SSi Robotic's FLASH™ System Selected by Invitrogen
Gene Logic Introduces ASCENTA® System 2.0
ReNeuron Develops Human Hepatocyte Cell Lines
Spotfire Launches Microarray Application
GeneGo Combines MetaDrug™ and Accelrys' Accord Technology
Bioreason Unveils ClassPharmer Suite
GE Healthcare Releases ADME Rat Microarray
Millipore and Caliper Develop HT Protocols
Waters Introduces Waters® MassTrak
Bio-Rad Laboratories Inc., Introduces ADMET Databases
Molecular Devices Corporation Launches Assay Kits for Early ADME Screening
Thermo Electron (Thermo Fisher Scientific) Introduces LeadStream ADME/Tox Solution™
Beckman Coulter Inc., Launches Biomek FX ADMETox Workstation
More.....

7. Regional Market Analysis

A. The United States

US Market Analysis

Exhibit 75: ADME/Tox Technologies (2005-2012) – United States Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

Exhibit 76: List of Major Companies in The United States

Analysis by Technology

Exhibit 77: ADME/Tox Technologies (2005-2012) – United States Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 78: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of United States Market Value by Predictive Technology for In Vivo, In Vitro and In Silico (*Graphical Representation included*)

Market for Related Technologies in The United States

US Market for HTS

Exhibit 79: High Throughput Screening (HTS) (2005-2012) – United States Market Analysis (Current & Future) in US\$ Billion (*Graphical Representation included*)

US Spending on HTS for Lead Discovery

Exhibit 80: High Throughput Screening (HTS) (2005-2012) – United States Spending for Lead Discovery in US\$ Million (*Graphical Representation included*)

US Market for Cell Based Assays

Exhibit 81: Cell-Based Assay (2005-2012) – United States Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

US Market for Pharma Contract Research

Exhibit 82: Pharmaceutical Contract Research (2005-2012) – United States Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

Exhibit 83: Number of Drugs with Potential Approval in the United States: 2005 – 2006 Estimates (*Graphical Representation included*)

B. Canada

Exhibit 84: ADME/Tox Technologies (2005-2012) – Canadian Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

Exhibit 85: List of Major Companies in Canada

Analysis by Technology

Exhibit 86: ADME/Tox Technologies (2005-2012) – Canadian Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 87: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Canadian Market Value by Predictive Technology for In Vivo, In Vitro and In Silico (*Graphical Representation included*)

Market for Related Technologies in Canada

Canadian Market for HTS

Exhibit 88: High Throughput Screening (HTS) (2005-2012) – Canadian Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

Canadian Market for Cell Based Assays

Exhibit 89: Cell-Based Assay (2005-2012) – Canadian Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

Canadian Market for Biotech R&D

Exhibit 90: Biotechnology R&D Expenditure (2005-2012) – Canadian Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

C. Europe

Exhibit 91: ADME/Tox Technologies (2005-2012) – European Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

Exhibit 92: List of Major Companies in Europe

Analysis by Geographic Region

Exhibit 93: ADME/Tox Technologies (2005-2012) – European Market Analysis (Current & Future) by Geographic Region for UK, Germany, France, Sweden, Finland, Italy and Rest of Europe in US\$ Million (*Graphical Representation included*)

Exhibit 94: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of European Market Value by Geographic Region for UK, Germany, France, Sweden, Finland, Italy and Rest of Europe (*Graphical Representation included*)

Analysis by Segment

Exhibit 95: ADME/Tox Technologies (2005-2012) – European Market Analysis (Current & Future) by Segment for Services and Technology in US\$ Million (*Graphical Representation included*)

Exhibit 96: ADME/Tox Technologies (2006, 2009 and 2012): Percentage

Breakdown of European Market Value by End-Use Sector for Services and Technology (*Graphical Representation included*)

Analysis by Technology

Exhibit 97: ADME/Tox Technologies (2005-2012) – European Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 98: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of European Market Value by Predictive Technology for In Vivo, In Vitro and In Silico (*Graphical Representation included*)
Market for Related Technologies in Europe

European Market for HTS

Exhibit 99: High Throughput Screening (HTS) (2005-2012) – European Market Analysis (Current & Future) in US\$ Billion (*Graphical Representation included*)

European Spending on HTS for Lead Discovery

Exhibit 100: High Throughput Screening (HTS) (2005-2012) – European Spending for Lead Discovery in US\$ Billion (*Graphical Representation included*)

European Market for Cell Based Assays

Exhibit 101: Cell-Based Assay (2005-2012) – European Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

European Market for Drug Discovery

Exhibit 102: Drug Discovery (2005-2012) – European Market Analysis (Current & Future) in US\$ Billion (*Graphical Representation included*)

European Market for Drug Discovery Outsourcing

Exhibit 103: Drug Discovery Outsourcing (2005-2012) – European Market Analysis (Current & Future) in US\$ Billion (*Graphical Representation included*)

European Market for Nanotechnology Based Drug Discovery

Exhibit 104: Drug Discovery Based on Nanotechnology (2005-2012) – European Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

European Biotechnology Market

Exhibit 105: Biotechnology R&D Expenditure (2005-2012) – European Market Analysis (Current & Future) in US\$ Billion (*Graphical Representation included*)

European ADME/Tox Market by Country

C1. The United Kingdom

Major Companies in UK ADME/Tox Market

UK Market Analysis

Exhibit 106: ADME/Tox Technologies (2005-2012) – UK Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 107: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of UK Market Value by Predictive Technology for In Vivo, In Vitro and In Silico (*Graphical Representation included*)

C2. Germany

Major Companies in German ADME/Tox Market

German Market Analysis

Exhibit 108: ADME/Tox Technologies (2005-2012) – German Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 109: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of German Market Value by Predictive Technology for In Vivo, In Vitro and In Silico (*Graphical Representation included*)

C3. France

Major Companies in French ADME/Tox Market

French Market Analysis

Exhibit 110: ADME/Tox Technologies (2005-2012) – French Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 111: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of French Market Value by Predictive Technology for In Vivo, In Vitro and In Silico

C4. Finland

Major Companies in Finnish ADME/Tox Market

Finnish Market Analysis

Exhibit 112: ADME/Tox Technologies (2005-2012) – Finnish Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 113: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Finnish Market Value by Predictive Technology for In Vivo, In Vitro and In Silico

C5. Italy

Major Companies in Italian ADME/Tox Market

Italian Market Analysis

Exhibit 114: ADME/Tox Technologies (2005-2012) – Italian Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 115: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Italian Market Value by Predictive Technology for In Vivo, In Vitro and In Silico

C6. Sweden

Major Company in Swedish ADME/Tox Market

Swedish Market Analysis

Exhibit 116: ADME/Tox Technologies (2005-2012) – Swedish Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 117: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Swedish Market Value by Predictive Technology for In Vivo, In Vitro and In Silico

C7. Rest of Europe

Analysis by Geographic Region

Exhibit 118: ADME/Tox Technologies (2005-2012) – Rest of Europe Market Analysis (Current & Future) by Geographic Region for Switzerland, Hungary, Belgium, Austria, Spain and Other in US\$ Million (*Graphical Representation included*)

Exhibit 119: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Rest of Europe Market Value by Geographic Region for Switzerland, Hungary, Belgium, Austria, Spain and Other

Analysis by Technology

Exhibit 120: ADME/Tox Technologies (2005-2012) – Rest of Europe Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 121: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Rest of Europe Market Value by Predictive Technology for In Vivo, In Vitro and In Silico

D. Asia-Pacific

Exhibit 122: ADME/Tox Technologies (2005-2012) – Asia-Pacific Market Analysis in US\$ Million (*Graphical Representation included*)

Exhibit 123: List of Major Companies in Asia-Pacific

Analysis by Geographic Region

Exhibit 124: ADME/Tox Technologies (2005-2012) – Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Japan, China, India, Australia and Rest of Asia-Pacific in US\$ Million (*Graphical Representation included*)

Exhibit 125: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Japan, China, India, Australia and Rest of Asia-Pacific

Analysis by Technology

Exhibit 126: ADME/Tox Technologies (2005-2012) – Asia-Pacific Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 127: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Asia-Pacific Market Value by Predictive Technology for In Vivo, In Vitro and In Silico

Drug Discovery Scenario in Asia-Pacific

Asia-Pacific Market for HTS

Exhibit 128: High Throughput Screening (HTS) (2005-2012) – Asia-Pacific Market Analysis (Current & Future) in US\$ Million (*Graphical Representation included*)

Asia-Pacific Market for Drug Discovery

Exhibit 129: Drug Discovery (2005-2012) – Asia-Pacific Market Analysis (Current & Future) in US\$ Billion (*Graphical Representation included*)

Asia-Pacific Market for Pharma CROs

Exhibit 130: Pharmaceutical Contract Research Organization (CROs) (2005-2012) – Asia-Pacific Market Analysis (Current & Future) in US\$ Billion (*Graphical Representation included*)

Asia-Pacific ADME/Tox Market by Country

D1. Japan

Major Companies in Japanese ADME/Tox Market

Japanese Market Analysis

Exhibit 131: ADME/Tox Technologies (2005-2012) – Japanese Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 132: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Japanese Market Value by Predictive Technology for In Vivo, In Vitro and In Silico

D2. China

Major Companies in Chinese ADME/Tox Market

Chinese Market Analysis

Exhibit 133: ADME/Tox Technologies (2005-2012) – Chinese Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 134: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Chinese Market Value by Predictive Technology for In Vivo, In Vitro and In Silico

D3. India

Major Companies in Indian ADME/Tox Market

Indian Market Analysis

Exhibit 135: ADME/Tox Technologies (2005-2012) – Indian Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 136: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Indian Market Value by Predictive Technology for In Vivo, In Vitro and In Silico

D4. Australia

Australian Market Analysis

Exhibit 137: ADME/Tox Technologies (2005-2012) – Australian Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 138: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Australian Market Value by Predictive Technology for In Vivo, In Vitro and In Silico (*Graphical Representation included*)

D5. Rest of Asia-Pacific

Rest of Asia-Pacific Market Analysis

Analysis by Geographic Region

Exhibit 139: ADME/Tox Technologies (2005-2012) – Rest of Asia-Pacific Market Analysis (Current & Future) by Geographic Region for South Korea, Singapore, Hong Kong and Other in US\$ Million (*Graphical Representation included*)

Exhibit 140: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Rest of Asia-Pacific Market Value by Geographic Region South Korea, Singapore, Hong Kong and Other (*Graphical Representation included*)

Analysis by Technology

Exhibit 141: ADME/Tox Technologies (2005-2012) – Rest of Asia-Pacific Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 142: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Rest of Asia-Pacific Market Value by Predictive Technology for In Vivo, In Vitro and In Silico (*Graphical Representation included*)

E. Rest of World

Latin America

Middle East

Africa

Exhibit 143: List of Major Companies in Rest of World

Rest of World Market AnalysisExhibit 144: ADME/Tox Technologies (2005-2012) – Rest of World Market Analysis (Current & Future) by Predictive Technology for In Vivo, In Vitro and In Silico in US\$ Million (*Graphical Representation included*)

Exhibit 145: ADME/Tox Technologies (2006, 2009 and 2012): Percentage Breakdown of Rest of Asia-Pacific Market Value by Predictive Technology for In Vivo, In Vitro and In Silico (*Graphical Representation included*)

8. ADME/Tox Technologies – The Industry Outlook

V. CORPORATE DIRECTORY